Literature DB >> 10619511

Simian virus 40 is present in most United States human mesotheliomas, but it is rarely present in non-Hodgkin's lymphoma.

P Rizzo1, M Carbone, S G Fisher, C Matker, L J Swinnen, A Powers, I Di Resta, S Alkan, H I Pass, R I Fisher.   

Abstract

Simian virus 40 (SV40) causes mesotheliomas, osteosarcomas, ependymomas, choroid plexus tumors, and lymphomas in hamsters. In humans, SV40 has been detected in tumors of the first four types. Using the polymerase chain reaction (PCR), we tested 29 non-Hodgkin's lymphomas (intermediate and high-grade), 25 posttransplant lymphoproliferative disorders, and 5 AIDS lymphomas for SV40 DNA. PCR analysis revealed that 3 of 29 lymphomas, 6 of 25 posttransplant lymphoproliferative disorders, and 2 of 5 AIDS lymphomas contained SV40 sequences corresponding to the retinoblastoma (RB)-pocket binding domain of SV40 tumor antigen (Tag). However, among positive samples, only one posttransplant lymphoproliferative disorder and one AIDS lymphoma contained the SV40 regulatory region, which suggest a higher viral load in these patients. In parallel experiments, 8 of 12 mesotheliomas tested positive for SV40 for both the RB-pocket binding domain of Tag and the SV40 regulatory region. These data confirm the presence of SV40 in most United States mesotheliomas and indicate that in human non-Hodgkin's lymphomas, the prevalence of SV40 is low.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10619511     DOI: 10.1378/chest.116.suppl_3.470s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  13 in total

1.  Simian virus 40 infection of humans.

Authors:  Robert L Garcea; Michael J Imperiale
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

Review 2.  What's the place of immunotherapy in malignant mesothelioma treatments?

Authors:  Marc Grégoire
Journal:  Cell Adh Migr       Date:  2010-01-30       Impact factor: 3.405

3.  Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity.

Authors:  M Bocchetta; I Di Resta; A Powers; R Fresco; A Tosolini; J R Testa; H I Pass; P Rizzo; M Carbone
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

4.  Presence of simian virus 40 DNA sequences in egyptian patients with lymphoproliferative disorders.

Authors:  Waleed S Mohamed; Mohamed A Samra; Mohamed A Fawzy
Journal:  Int J Health Sci (Qassim)       Date:  2007-01

Review 5.  Emergent human pathogen simian virus 40 and its role in cancer.

Authors:  Regis A Vilchez; Janet S Butel
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

Review 6.  Simian virus 40 and its association with human lymphomas.

Authors:  Regis A Vilchez; Janet S Butel
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

7.  Absence of simian virus 40 DNA sequences in primary central nervous system lymphoma in HIV-negative patients.

Authors:  Manuel Montesinos-Rongen; Razvan Besleaga; Susanne Heinsohn; Reiner Siebert; Hartmut Kabisch; Otmar D Wiestler; Martina Deckert
Journal:  Virchows Arch       Date:  2004-03-24       Impact factor: 4.064

8.  First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial.

Authors:  Ó Arrieta; L A Medina; E Estrada-Lobato; N Hernández-Pedro; G Villanueva-Rodríguez; L Martínez-Barrera; E O Macedo; V López-Rodríguez; D Motola-Kuba; J F Corona-Cruz
Journal:  Br J Cancer       Date:  2012-02-21       Impact factor: 7.640

9.  Thirty-five year mortality following receipt of SV40- contaminated polio vaccine during the neonatal period.

Authors:  C Carroll-Pankhurst; E A Engels; H D Strickler; J J Goedert; J Wagner; E A Mortimer
Journal:  Br J Cancer       Date:  2001-11-02       Impact factor: 7.640

10.  Simian virus 40 in humans.

Authors:  Fernanda Martini; Alfredo Corallini; Veronica Balatti; Silvia Sabbioni; Cecilia Pancaldi; Mauro Tognon
Journal:  Infect Agent Cancer       Date:  2007-07-09       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.